OLMAOlema Pharmaceuticals, Inc.
$7.81-25% 1Y
$7.81
$7.7752 weeks$35.83
Price
-25%1YEnd-of-day closes, not the intraday tick.
RyuScore
Weak, higher than 2% of companiesThe five questions
2 of 5 availableOnly two of the five can be answered for OLMA today. The rest need figures this filer has not published. The tabs above still show whatever data does exist.
- Is the business good?not enough filed
- Is it safe?Watch
- Is the price fair?not enough filed
- Is it growing?not enough filed
- What is the market doing?Watch
P/En/a
Market value$682.2M
1 year-25%
5 years-72%
Charts
As reported to the SEC, without any scoring.
The next results filing is expected around Nov 9, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 13, 2026On August 13, 2026, Olema Pharmaceuticals, Inc. (the “Company”) announced the appointment of Jason O’Byrne as the Company’s Chief Financial Officer, principal financial officer and principal accounting officer, which was approved by the Board of Directors of the Company (the “Board”) on July 28, 2026 and effective as …Director or officer change · Form 8-K
- Aug 10, 2026Olema Oncology Reports Second Quarter 2026 Financial and Operating Results.Earnings release · press release
- May 26, 2026As described above, on May 26, 2026, the Company announced that it had entered into the Agreement with Bayer.Regulation FD disclosure · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.